New study identifies top complement inhibitor for geographic atrophy in AMD
Avacincaptad pegol 2 mg stands out as the most effective and safest complement inhibitor for reducing geographic atrophy lesion size in patients with AMD, compared to other treatments like pegcetacoplan, which carries a higher risk of macular neovascularization, according to a new study.
The systematic review and network meta-analysis incorporated data from 10 randomized controlled trials with 4,405 participants and compared the effectiveness and safety of 5 complement inhibitors.
The primary focus was on GA lesion size reduction over 12 months.
The analysis found that avacincaptad pegol 2 mg was the most effective treatment for reducing GA lesion size (mean difference: -0.58 mm², 95% CrI: -0.97 to -0.18), with the highest SUCRA ranking (93.55). Monthly administration of pegcetacoplan also showed significant, though less pronounced, reductions in lesion size.
Monthly pegcetacoplan was associated with a higher risk of macular neovascularization (OR: 4.30, 95% CrI: 1.48–16.72), while avacincaptad pegol showed a more favorable safety profile with fewer serious adverse events.
Reference
Wang H, Zheng J, Zhang Q, et al. Efficacy and safety of complement inhibitors in patients with geographic atrophy associated with age-related macular degeneration: a network meta-analysis of randomized controlled trials. Front Pharmacol. 2024;15:1410172. doi: 10.3389/fphar.2024.1410172. PMID: 39600369; PMCID: PMC11589381.
This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.
